Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 53.5 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,yervoy, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),yervoy, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),yervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),yervoy, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),yervoy in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - aztreonam, quantity: 1 g - injection, powder for - excipient ingredients: arginine - indications as at 23 may 1991: 1. azactam is indicated for use as a single agent in the treatment of infections known or strongly suspected to be due to susceptible gram negative aerobes, such as urinary tract infection, gonorrhoea, etc. 2. in combination with other suitable antibiotics to treat serious infections due to problem organisms known or likely to be susceptible to aztreonam. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an aminoglycoside because of synergistic action. however, this enhanced activity is not predictable. if such concurrent therapy is considered in patients with serious infections, susceptibility tests should be performed in vitro to determine the activity of the drugs in combination. because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics, renal function should be monitored according to the aminoglycoside manufacturer's prescribing information, especially if high dosages of the aminoglycoside are to be u

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - lomustine 10mg - capsule - 10 mg - active: lomustine 10mg excipient: gelatin magnesium stearate mannitol opacode black s-1-27794 titanium dioxide - ceenu is indicated as palliative therapy to be employed in addition to other modalities, or in established combination therapy with other approved chemotherapeutic agents in the following: 1. brain tumours - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - lomustine 40mg - capsule - 40 mg - active: lomustine 40mg excipient: gelatin indigo carmine iron oxide yellow magnesium stearate mannitol opacode black s-1-27794 titanium dioxide   - ceenu is indicated as palliative therapy to be employed in addition to other modalities, or in established combination therapy with other approved chemotherapeutic agents in the following: 1. brain tumours - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) - injection (depot) - 25 mg/ml - active: fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) excipient: benzyl alcohol nitrogen sesame oil - fluphenazine decanoate is indicated in the long-term management of psychotic disorders including schizophrenia, mania and organic brain syndrome. it is of particular value in the treatment of chronic schizophrenia and for patients who are unreliable at taking oral medication. the drug often alleviates such target symptoms as hallucinations, delusions, confusion and withdrawal. it is not only useful in the hospital milieu but is unparalleled, because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. fluphenazine decanoate has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - fluphenazine decanoate 100 mg/ml - injection (depot) - 100 mg/ml - active: fluphenazine decanoate 100 mg/ml excipient: benzyl alcohol sesame oil - fluphenazine decanoate is indicated in the long-term management of psychotic disorders including schizophrenia, mania and organic brain syndrome. it is of particular value in the treatment of chronic schizophrenia and for patients who are unreliable at taking oral medication. the drug often alleviates such target symptoms as hallucinations, delusions, confusion and withdrawal. it is not only useful in the hospital milieu but is unparalleled, because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. fluphenazine decanoate has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 100mg;   - film coated tablet - 100 mg - active: dasatinib 100mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 20mg;   - film coated tablet - 20 mg - active: dasatinib 20mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 50mg;   - film coated tablet - 50 mg - active: dasatinib 50mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 70mg;   - film coated tablet - 70 mg - active: dasatinib 70mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase